CRL — Charles River Laboratories International Income Statement
0.000.00%
Last trade - 00:00
- $14.00bn
- $16.43bn
- $4.13bn
- 94
- 31
- 91
- 83
2019 December 28th | 2020 December 26th | 2021 December 25th | 2022 December 31st | 2023 December 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,621 | 2,924 | 3,540 | 3,976 | 4,129 |
Cost of Revenue | |||||
Gross Profit | 958 | 1,074 | 1,335 | 1,463 | 1,529 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2,270 | 2,491 | 2,928 | 3,305 | 3,389 |
Operating Profit | 351 | 433 | 613 | 671 | 741 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 304 | 447 | 481 | 623 | 581 |
Provision for Income Taxes | |||||
Net Income After Taxes | 254 | 365 | 399 | 493 | 480 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 252 | 364 | 391 | 486 | 475 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 252 | 364 | 391 | 486 | 475 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.71 | 7.63 | 7.98 | 9.3 | 7.92 |